Key result
Catechin pretreatment reverses doxorubicin-induced cardiotoxicity in rats by improving antioxidant enzymes and reducing injury biomarkers.
Why the study?
Cardiotoxicity is the most important side effect limiting the clinical use of doxorubicin, prompting investigation into the protective role of catechin.
Does catechin prevent doxorubicin-induced cardiotoxicity in adult male albino rats?
Population
Adult male albino rats
Comparison
Control vs DOX alone vs CAT pretreatment plus DOX with CAT
Design
Randomized preclinical study
Authors
Loading...
Hypothesis-generating in rat models; does not support clinical use of catechin and requires human trials.
RCT
Randomly divided
Does catechin prevent doxorubicin-induced cardiotoxicity in adult male albino rats?
p-value: p=<0.001
Catechin shows potential as a cardioprotective agent against doxorubicin-induced cardiotoxicity in a preclinical rat model by reducing oxidative stress and apoptosis.
A. Saleh (2021) conducted an RCT in Doxorubicin-induced cardiotoxicity. Catechin vs. Doxorubicin alone (1.66 mg/kg i.p.) and untreated control was evaluated on Cardiac tissue levels of oxidative stress markers and serum cardiac injury biomarkers (p=<0.001). Catechin pretreatment reversed doxorubicin-induced cardiotoxicity, significantly improving antioxidant enzyme levels and reducing cardiac injury biomarkers (p < 0.001) in adult male rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: